Literature DB >> 15731113

Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1).

Stephen Fasciano1, Rekha C Patel, Indhira Handy, Chandrashekhar V Patel.   

Abstract

Uncontrolled proliferation of vascular smooth muscle cells (VSMCs) contribute to intimal hyperplasia during atherosclerosis and restenosis. Heparin is an antiproliferative agent for VSMCs and has been shown to block VSMC proliferation both in tissue culture systems and in animals. Despite the well documented antiproliferative actions of heparin, its cellular targets largely remain unknown. In an effort to characterize the mechanism of the antiproliferative property of heparin, we have analyzed the effect of heparin on cell cycle in VSMC. Our results indicate that the heparin-induced block in G(1) to S phase transition is imposed by p27(kip1)-mediated inhibition of cyclin-dependent kinase 2 activity. Further analysis of p27(kip1) mRNA levels showed that the increase in p27(kip1) protein levels in heparin-treated VSMC occurs at posttranscriptional levels. We present evidence that heparin causes stabilization of p27(kip1) protein during G(1) phase and thereby prevents activation of cyclin-dependent kinase 2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731113      PMCID: PMC3972062          DOI: 10.1074/jbc.M411458200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  98 in total

1.  Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators.

Authors:  J J Young; D J Kereiakes; C L Grines
Journal:  J Invasive Cardiol       Date:  2000-12       Impact factor: 2.022

2.  Transcriptional regulation by the retinoblastoma protein.

Authors:  T Kouzarides
Journal:  Trends Cell Biol       Date:  1993-07       Impact factor: 20.808

3.  Collagen type I enhances endothelin-mediated contraction and induces nonproliferating phenotype in mesangial cells.

Authors:  T Miralem; C I Whiteside; D M Templeton
Journal:  Am J Physiol       Date:  1996-06

4.  Inhibition of smooth muscle cell proliferation by heparin molecules.

Authors:  A W Clowes; M M Clowes
Journal:  Transplant Proc       Date:  1989-08       Impact factor: 1.066

5.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

6.  Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.

Authors:  D Chen; K Krasinski; A Sylvester; J Chen; P D Nisen; V Andrés
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

7.  Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1).

Authors:  D E Marra; T Simoncini; J K Liao
Journal:  Circulation       Date:  2000-10-24       Impact factor: 29.690

Review 8.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

9.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

10.  Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells.

Authors:  Y P Au; K F Montgomery; A W Clowes
Journal:  Circ Res       Date:  1992-05       Impact factor: 17.367

View more
  13 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

2.  Heparin treatment of vascular smooth muscle cells results in the synthesis of the dual-specificity phosphatase MKP-1.

Authors:  Cheryl Isleib Blaukovitch; Raymond Pugh; Albert C Gilotti; Daniela Kanyi; Linda J Lowe-Krentz
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

3.  Mechanistic characterization of the 5'-triphosphate-dependent activation of PKR: lack of 5'-end nucleobase specificity, evidence for a distinct triphosphate binding site, and a critical role for the dsRBD.

Authors:  Rebecca Toroney; Chelsea M Hull; Joshua E Sokoloski; Philip C Bevilacqua
Journal:  RNA       Date:  2012-08-21       Impact factor: 4.942

4.  Growth arrest of vascular smooth muscle cells in suspension culture using low-acyl gellan gum.

Authors:  Tomomi Natori; Masachika Fujiyoshi; Masashi Uchida; Natsuki Abe; Tatsuro Kanaki; Yasunori Fukumoto; Itsuko Ishii
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-12-06       Impact factor: 2.416

5.  Endothelial nitric oxide synthase activation is required for heparin receptor effects on vascular smooth muscle cells.

Authors:  Yaqiu Li; Leanna M Talotta-Altenburg; Kayli A Silimperi; Grace O Ciabattoni; Linda J Lowe-Krentz
Journal:  Am J Physiol Cell Physiol       Date:  2019-12-31       Impact factor: 4.249

6.  Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/Rho kinase/p27.

Authors:  Lunyin Yu; Deborah A Quinn; Hari G Garg; Charles A Hales
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-17       Impact factor: 6.914

7.  Different responses of cell cycle between rat vascular smooth muscle cells and vascular endothelial cells to paclitaxel.

Authors:  Liang Jing; Xi Peng; Min-Jie Xie; Zhi-Yuan Yu; Wei Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

8.  The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.

Authors:  Y Carmazzi; M Iorio; C Armani; S Cianchetti; F Raggi; T Neri; C Cordazzo; S Petrini; R Vanacore; F Bogazzi; P Paggiaro; A Celi
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

9.  Heparin responses in vascular smooth muscle cells involve cGMP-dependent protein kinase (PKG).

Authors:  Albert C Gilotti; Wutigri Nimlamool; Raymond Pugh; Joshua B Slee; Trista C Barthol; Elizabeth A Miller; Linda J Lowe-Krentz
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

10.  Transmembrane Protein 184A Is a Receptor Required for Vascular Smooth Muscle Cell Responses to Heparin.

Authors:  Raymond J Pugh; Joshua B Slee; Sara Lynn N Farwell; Yaqiu Li; Trista Barthol; Walter A Patton; Linda J Lowe-Krentz
Journal:  J Biol Chem       Date:  2016-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.